How to translate text using browser tools
31 July 2022 Genomic testing in premature ovarian insufficiency: proceed with caution
Elena J. Tucker, Tiong Y. Tan, Zornitza Stark, Andrew H. Sinclair
Author Affiliations +
Abstract

Genomic testing has the potential to transform outcomes for women with infertility conditions, such as premature ovarian insufficiency (POI), with growing calls for widespread diagnostic use. The current research literature, however, often uses poor variant curation leading to inflated diagnostic claims and fails to address the complexities of genomic testing for this condition. Without careful execution of the transition from research to the clinic, there is danger of inaccurate diagnoses and poor appreciation of broader implications of testing. This Forum outlines the benefits of genomic testing for POI and raises often overlooked concerns.

Summary Sentence

Genomic testing has the potential to improve outcomes for women with infertility; however, thorough counseling, rigorous variant curation, and realistic expectations are required for optimal outcomes.

Graphical Abstract

img-z1-16_1155.jpg
© The Author(s) 2022. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
Elena J. Tucker, Tiong Y. Tan, Zornitza Stark, and Andrew H. Sinclair "Genomic testing in premature ovarian insufficiency: proceed with caution," Biology of Reproduction 107(5), 1155-1158, (31 July 2022). https://doi.org/10.1093/biolre/ioac153
Received: 15 June 2022; Accepted: 20 July 2022; Published: 31 July 2022
KEYWORDS
female infertility
genomic testing
human reproduction
pleiotropy
premature ovarian insufficiency
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top